Bone Biologics Corp — Director's Dealing 2024

Jan 10, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bone Biologics Corp (BBLG)
CIK: 0001419554
Period of Report: 2024-01-08

Reporting Person: Gagnon Robert E. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-08	Non-Employee Stock Option	$4.68	A	9	Acquired	2034-01-08	Common Stock (9)	Direct
2024-01-08	Non-Employee Stock Option	$4.68	A	8.006	Acquired	2034-01-08	Common Stock (8006)	Direct

Footnotes

F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable on the date of the next annual meeting of the stockholders of the Company following the grant date.

F2: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, 2,003 options are immediately exercisable with the remaining 6,003 options vesting and becoming exercisable in three equal installments on 3/12/2024, 6/12/2024, and 9/12/2024.